Medicare Coverage Updated to Include the BRACAnalysis®
Large Rearrangement Test!

The BRACAnalysis® Large Rearrangement Test (BART™) provides a way to detect large genomic rearrangements in BRCA1 and BRCA2 that are not identified as part of the BRACAnalysis sequencing test. Large rearrangement mutations account for 6-10% of all Hereditary Breast and Ovarian Cancer (HBOC) mutations identified.

As of October 1, 2012, the Medicare coverage policy states*:
“Comprehensive genetic testing of BRCA1 and BRCA2 includes full sequencing and detection of large genomic rearrangements.”

BART testing will be covered for Medicare patients meeting one of the criteria for BRCA1/2 testing listed in the policy which is summarized below. The complete medical policy may be accessed on-line via the link on www.myriadpro.com/medicarecriteria.

Patients with a personal history of breast cancer who:

- were diagnosed at or before age 45
- were diagnosed at or before age 50 or with two breast primaries and have either:
  - one or more close blood relative(s) with breast cancer at or before age 50, OR
  - one or more close blood relative(s) with epithelial ovarian/fallopian tube/primary peritoneal cancer
- were diagnosed with two primary breast cancers, the first of which occurred prior to age 50
- were diagnosed before age 60 with a triple negative breast cancer (ER-, PR-, HER2-)
- were diagnosed before age 50 with a limited family history†
- were diagnosed at any age, with either:
  - two or more close blood relatives with breast and/or epithelial ovarian/fallopian tube/primary peritoneal cancer, at any age, OR
  - a close male blood relative with breast cancer
- are of Ashkenazi Jewish descent
- have a close relative with a known BRCA1 or BRCA2 gene mutation

Patients with a personal history of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Patients with a personal history of male breast cancer

The following items must be submitted with the patient’s sample:
- Completed Test Request Form
- Copies of the patient’s insurance card(s)
- Signed Informed Consent

If a patient does not meet criteria, a completed Advance Beneficiary Notice of Noncoverage (ABN) is required.

Please direct any questions regarding Myriad’s testing services to your local Myriad Account Executive or call Customer Service at (800) 469-7423.


*Subject to change without notice
†Defined as fewer than two first- or second-degree female relatives or female relatives surviving beyond 45 years in either lineage

Myriad, the Myriad logo, BRACAnalysis, the BRACAnalysis logo, and BART are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. ©2012